Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006

crackpot submitted, created time 1 year 7 months (www.kinetoplastids.com)

"According to the experts from different endemic countries present, the financial and social burdens of CL are high, but they have limited quantitative data. The analysis of published trials indicates that the quality of most trials is poor and requires both improvement and standardization. The available drugs are inadequate. Criteria by which different CL types could be prioritized as target disease were set

Submit comment | Blog It | Email It | Keywords: disease cutaneous leishmaniasis disease treatment immune disease